Peripheral neuropathy exacerbated by lenalidomide in a patient with multiple myeloma

Tomohiko Kamimura, Toshihiro Miyamoto, Noriko Yokota, Takatoshi Aoki, Yoshikiyo Ito, Koichi Akashi

研究成果: ジャーナルへの寄稿学術誌査読

抄録

We evaluated a serial change in peripheral neuropathy (PN) severity during treatment with bortezomib (Bor) or lenalidomide (Len) using the Functional Assessment of Cancer Therapy scale/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx). The patient suffered from grade 2 PN and exhibited a dramatic decrease in FACT/GOG-Ntx score after intravenous and subcutaneous Bor therapy. Thereafter, he received seven cycles of Len therapy, which exacerbated existing PN; he experienced mild numbness and exhibited a transient decrease in FACT/GOG-Ntx score. Interestingly, FACT/GOG-Ntx score increased to baseline and numbness was ameliorated during the Len washout period in every cycle.

本文言語英語
ページ(範囲)1651-1653
ページ数3
ジャーナルInternal Medicine
53
15
DOI
出版ステータス出版済み - 2014

!!!All Science Journal Classification (ASJC) codes

  • 内科学

フィンガープリント

「Peripheral neuropathy exacerbated by lenalidomide in a patient with multiple myeloma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル